William Blair & Company’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$19.3M Buy
126,421
+45,143
+56% +$6.92M 0.06% 250
2025
Q4
$11.2M Buy
81,278
+15,552
+24% +$2.04M 0.03% 335
2025
Q3
$8.43M Sell
65,726
-381
-0.6% -$46.5K 0.02% 403
2025
Q2
$8M Sell
66,107
-10,415
-14% -$1.17M 0.02% 396
2025
Q1
$8.53M Sell
76,522
-3,730
-5% -$397K 0.03% 360
2024
Q4
$7.81M Sell
80,252
-567
-0.7% -$60.5K 0.02% 390
2024
Q3
$9.3M Sell
80,819
-343
-0.4% -$38.9K 0.03% 356
2024
Q2
$8.64M Sell
81,162
-823
-1% -$82.6K 0.03% 348
2024
Q1
$7.93M Sell
81,985
-3,266
-4% -$335K 0.02% 373
2023
Q4
$8.61M Buy
85,251
+560
+0.7% +$54.1K 0.03% 346
2023
Q3
$8.63M Sell
84,691
-2,292
-3% -$233K 0.03% 331
2023
Q2
$8.78M Sell
86,983
-1,781
-2% -$178K 0.03% 336
2023
Q1
$8.17M Sell
88,764
-1,956
-2% -$171K 0.03% 344
2022
Q4
$8.23M Sell
90,720
-8,130
-8% -$685K 0.04% 329
2022
Q3
$7.51M Sell
98,850
-100
-0.1% -$8.29K 0.03% 331
2022
Q2
$8.36M Sell
98,950
-1,215
-1% -$107K 0.04% 321
2022
Q1
$8.79M Sell
100,165
-884
-0.9% -$76.5K 0.03% 345
2021
Q4
$8.84M Buy
101,049
+10,304
+11% +$856K 0.03% 364
2021
Q3
$7.42M Sell
90,745
-4,756
-5% -$428K 0.03% 378
2021
Q2
$8.71M Sell
95,501
-34,468
-27% -$3.07M 0.03% 348
2021
Q1
$11.1M Sell
129,969
-23,444
-15% -$2.1M 0.04% 304
2020
Q4
$14.5M Sell
153,413
-56,204
-27% -$4.91M 0.05% 249
2020
Q3
$18.2M Buy
209,617
+13,065
+7% +$1.13M 0.08% 199
2020
Q2
$17.2M Sell
196,552
-12,893
-6% -$1.11M 0.08% 200
2020
Q1
$17.3M Sell
209,445
-8,234
-4% -$735K 0.11% 170
2019
Q4
$20.6M Buy
217,679
+42,785
+24% +$3.84M 0.11% 188
2019
Q3
$15.2M Sell
174,894
-10,595
-6% -$951K 0.09% 202
2019
Q2
$16.9M Sell
185,489
-15,325
-8% -$1.3M 0.1% 194
2019
Q1
$17.3M Buy
200,814
+2,194
+1% +$176K 0.11% 183
2018
Q4
$15.3M Buy
198,620
+3,568
+2% +$278K 0.11% 178
2018
Q3
$15.1M Buy
195,052
+1,632
+0.8% +$121K 0.09% 200
2018
Q2
$13.1M Sell
193,420
-7,527
-4% -$519K 0.09% 209
2018
Q1
$14.6M Sell
200,947
-122,456
-38% -$9.32M 0.1% 184
2017
Q4
$24.3M Buy
323,403
+119,710
+59% +$9.03M 0.17% 137
2017
Q3
$15.7M Buy
203,693
+5,724
+3% +$432K 0.12% 180
2017
Q2
$14.8M Buy
197,969
+30,961
+19% +$2.19M 0.11% 195
2017
Q1
$11.2M Sell
167,008
-1,136
-0.7% -$75.7K 0.09% 214
2016
Q4
$11M Buy
168,144
+5,274
+3% +$342K 0.1% 208
2016
Q3
$11.5M Sell
162,870
-11,690
-7% -$852K 0.1% 199
2016
Q2
$12.9M Sell
174,560
-15,703
-8% -$1.08M 0.12% 185
2016
Q1
$12.3M Sell
190,263
-4,700
-2% -$320K 0.12% 179
2015
Q4
$15M Sell
194,963
-43,812
-18% -$3.48M 0.14% 163
2015
Q3
$19.7M Buy
238,775
+9,748
+4% +$868K 0.17% 147
2015
Q2
$20.2M Buy
229,027
+13,341
+6% +$1.22M 0.03% 641
2015
Q1
$19.1M Sell
215,686
-27,006
-11% -$2.4M 0.03% 622
2014
Q4
$20.1M Buy
242,692
+13,574
+6% +$1.13M 0.03% 593
2014
Q3
$19.3M Buy
229,118
+21,852
+11% +$1.77M 0.03% 582
2014
Q2
$16.8M Buy
207,266
+40,665
+24% +$3.2M 0.03% 635
2014
Q1
$12.7M Buy
166,601
+4,708
+3% +$343K 0.02% 737
2013
Q4
$11.7M Sell
161,893
-25,006
-13% -$1.74M 0.02% 745
2013
Q3
$12.8M Sell
186,899
-60,765
-25% -$4.02M 0.02% 658
2013
Q2
$15.7M Buy
+247,664
New +$16.1M 0.03% 550

Other funds holding NVS

William Blair & Company's NVS Position: Q1 2026 in Review

William Blair & Company increased its Novartis (NVS) stake by 56% in Q1 2026, buying an estimated $6.92M and bringing the position to 126,421 shares worth $19.3M. The position accounts for 0.06% of the portfolio, ranked #250.

William Blair & Company first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $24.3M in Q4 2017. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • William Blair & Company held 126,421 shares of Novartis worth $19.3M as of Q1 2026.
  • William Blair & Company bought 45,143 Novartis shares in Q1 2026, an estimated $6.92M.
  • Novartis made up 0.06% of William Blair & Company's portfolio in Q1 2026, its #250 holding.
  • William Blair & Company first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • William Blair & Company's Novartis position peaked at $24.3M in Q4 2017.
  • 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.